Cost-effectiveness analysis of treatment strategies initiating with second-generation antipsychotic long-acting injectables in patients with schizophrenia in the United States

Key Points

• This analysis aims to compare the cost-effectiveness of second-generation antipsychotic long-acting injectables for treating schizophrenia.
• Conducted cost-effectiveness analysis of treatment strategies
• Focused on second-generation antipsychotic long-acting injectables
• Evaluated impact on adherence and relapse risk in patients with schizophrenia
• Identified economic burden associated with schizophrenia treatment
• Demonstrated benefits in treatment adherence and relapse risk reduction with LAIs
• Provided comparative cost-effectiveness data on SGA LAIs in the U.S.